{"nctId":"NCT03001011","briefTitle":"Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China","startDateStruct":{"date":"2017-06-07","type":"ACTUAL"},"conditions":["Hyperphosphatemia"],"count":202,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Renvela","type":"EXPERIMENTAL","interventionNames":["Drug: Sevelamer Carbonate (GZ419831)"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Sevelamer Carbonate (GZ419831)","otherNames":["Renvela"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Participants with chronic kidney disease who had not been on dialysis, and were not expected to begin dialysis, or renal transplantation in the next 4 months from the screening visit.\n* Had serum phosphorus measurement greater than or equal to (\\>=) 5.5 mg/dL (1.78 mmol/L) at screening visit (if participants were not on phosphate binder\\[s\\] at Screening Visit) OR at the end of Washout Period (if participants were on phosphate binder\\[s\\] at screening visit).\n* Had the following laboratory measurements at screening visit:\n\n  * 25-hydroxy vitamin D \\>=10 nanograms per milliliter (ng/mL).\n  * intact parathyroid hormone, intact parathyroid hormone (iPTH) \\<=800 picograms per millilitre (pg/mL).\n  * Signed written informed consent.\n\nExclusion criteria:\n\n* Men or women below 18 years of age.\n* Any technical/administrative reason that made it impossible to randomize the participant in the study.\n* Was not of the level of understanding and willingness to cooperate with all visits and procedures, as described in the study protocol.\n* Not yet received chronic kidney disease diet education before screening visit.\n* Not willing and not able to avoid changes to diet during the study.\n* Not willing or able to maintain screening doses of lipid lowering medication, 1, 25 dihydroxy vitamin D, and/or cinacalcet for the duration of the study, except for safety reasons.\n* Not willing or not able to avoid antacids and phosphate binders containing aluminium, magnesium, calcium, or lanthanum for the duration of the study unless prescribed as an evening calcium supplement.\n* Had participated in any other investigational drug studies within 30 days, or 5 half lives, whichever is longer, prior to screening visit.\n* Conditions/situations such as:\n\n  * Participant was the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.\n  * Uncooperative or any condition that could make the participant potentially non-compliant to the study procedures (for example, participants could not be contacted by phones as required in phone call visits).\n  * Evidence of active malignancy.\n  * Not on stable medical condition (for example, but not limited to, active ethanol or drug abuse \\[tobacco use acceptable\\]; documented poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, human immunodeficiency virus \\[HIV\\] infection), or had any clinically significant medical conditions.\n* Had known hypersensitivity to sevelamer or any constituents of Renvela tablets.\n* Had bowel obstruction, active dysphagia or swallowing disorder, or a predisposition to or current bowel obstruction, ileus, or severe gastrointestinal motility disorders including severe constipation.\n* Using or plan to use anti-arrhythmic or anti-seizure medications for arrhythmia or seizure disorders.\n* Was pregnant or breast-feeding.\n* If the participant was female, and of childbearing potential (pre-menopausal and not surgically sterile), was not willing to use an effective contraceptive method throughout the study.\n* Had any condition, which in the opinion of the investigator would prohibit the participant's inclusion in the study.\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Serum Phosphorus at Week 8","description":"Baseline of serum phosphorus value was the last serum phosphorus level obtained before the first double-blind investigational medicinal product (IMP) dosing. Missing Week 8 data were imputed by last observation carried forward \\[LOCF\\] method.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.090","spread":null},{"groupId":"OG001","value":"2.095","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.010","spread":null},{"groupId":"OG001","value":"-0.200","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Cholesterol at Week 8","description":"Missing Week 8 data were imputed by LOCF method.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.115","spread":null},{"groupId":"OG001","value":"-0.830","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8","description":"Missing Week 8 data were imputed by LOCF method.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.030","spread":null},{"groupId":"OG001","value":"-0.830","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Calcium-Phosphorus Product at Week 8","description":"Missing Week 8 data were imputed by LOCF method.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0200","spread":null},{"groupId":"OG001","value":"-0.4960","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Intact Parathyroid Hormone (Ipth) Level at Week 8","description":"Missing Week 8 data were imputed by LOCF method.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2380","spread":null},{"groupId":"OG001","value":"0.0000","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching the Target Serum Phosphorus Level (4.6 mg/dL [1.49 mmol/L]) at Week 8","description":"Missing Week 8 data were imputed by LOCF method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null},{"groupId":"OG001","value":"15.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Phosphorus Level at Week 4","description":"Missing Week 4 data were imputed by LOCF method.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.020","spread":null},{"groupId":"OG001","value":"-0.240","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Event","description":"Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an Adverse Event (AE) without regard to possibility of causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during TEAE period. On-treatment period was defined as the (time from the first dose of IMP to the last dose of IMP+3 days). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Laboratory Abnormalities: Hematological Parameters","description":"Criteria for potentially clinically significant abnormalities:\n\n* Hemoglobin: \\<=115 g/L (Male\\[M\\]) or \\<=95 g/L (Female \\[F\\]); \\>=185 g/L (M) or \\>=165 g/L (F); Decrease from baseline (DFB) \\>=20 g/L\n* Hematocrit: \\<=0.37 v/v (M) or \\<=0.32 v/v (F); \\>=0.55 v/v (M) or \\>=0.5 v/v (F)\n* Red blood cells (RBC): \\>=6 Tera/L\n* Platelets: \\<100 Giga/L; \\>=700 Giga/L\n* White blood cells (WBC): \\<3.0 Giga/L (Non-Black \\[NB\\]) or \\<2.0 Giga/L (Black \\[B\\]); \\>=16.0 Giga/L\n* Neutrophils: \\<1.5 Giga/L (NB) or \\<1.0 Giga/L (B); \\<1.0 Giga/L\n* Lymphocytes: \\>4.0 Giga/L\n* Monocytes: \\>0.7 Giga/L\n* Basophils: \\>0.1 Giga/L\n* Eosinophils: \\>0.5 Giga/L or \\>upper limit of normal (ULN) (if ULN \\>=0.5 Giga/L)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Laboratory Abnormalities: Metabolic Parameters","description":"Criteria for potentially clinically significant abnormalities:\n\n* Glucose: \\<=3.9 mmol/L and \\< lower limits of normal (LLN); \\>=11.1 mmol/L (unfasted \\[unfas\\]) or \\>=7 mmol/L (fasted \\[fas\\])\n* Triglycerides: \\>=4.6 mmol/L\n* Albumin: \\<= 25 g/L.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Laboratory Abnormalities: Electrolytes","description":"Criteria for potentially clinically significant abnormalities:\n\nSodium: \\<=129 millimoles (mmol)/L; \\>=160 mmol/L Potassium: \\<3 mmol/L; \\>=5.5 mmol/L Chloride: \\<80 mmol/L; \\>115 mmol/L.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Laboratory Abnormalities: Renal Function Parameters","description":"Criteria for potentially clinically significant abnormalities:\n\nCreatinine: \\>=150 micromol/L; \\>=30% change from baseline, \\>=100% change from baseline Creatinine clearance: \\<15 mL/min; \\>=15 to \\<30 mL/min; \\>=30 to \\<60 mL/min; \\>=60 to \\<90 mL/min Blood urea nitrogen: \\>=17 mmol/L Uric acid: \\<120 micromol/L; \\>408 micromol/L Glomular Filtration Rate (GFR): \\< 15 mL/min/1.73m\\^2, \\>= 15 - \\< 30 mL/min/1.73m\\^2, \\>= 30 - \\< 60 mL/min/1.73m\\^2, \\>= 60 - \\< 90 mL/min/1.73m\\^2.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Laboratory Abnormalities: Liver Function Parameters","description":"Criteria for potentially clinically significant abnormalities:\n\nAlanine Aminotransferase (ALT): \\>3 ULN; \\>5 ULN; \\>10 ULN; Aspartate aminotransferase (AST): \\>3 ULN.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Vital Signs Abnormalities","description":"Criteria for potentially clinically significant vital sign abnormalities:\n\nSystolic blood pressure (SBP) supine: \\<=95 millimeters of mercury (mmHg) and DFB \\>=20 mmHg; \\>=160 mmHg and increase from baseline (IFB) \\>=20 mmHg Diastolic blood pressure (DBP) supine: \\<=45 mmHg and DFB \\>=10 mmHg; \\>=110 mmHg and IFB \\>=10 mmHg Heart rate (HR) supine: \\<=50 beats per minute (bpm) and DFB \\>=20 bpm; \\>=120 bpm and IFB \\>=20 bpm Weight: \\>=5% DFB; \\>=5% IFB.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":31,"n":101},"commonTop":["Hyperkalaemia","Nausea","Vomiting","Oedema Peripheral","Upper Respiratory Tract Infection"]}}}